Home » Topics » BioWorld Science

BioWorld Science
RSS

Guangzhou Henovcom Bioscience identifies new NR1H4 agonists

Feb. 25, 2020

GlaxoSmithKline and ViiV Healthcare present compounds for HIV infection

Feb. 25, 2020

Blue Sky Pharmaceuticals describes new mu-opioid receptor agonists for pain

Feb. 25, 2020

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents boric acid derivatives

Feb. 25, 2020

ASOs targeting GYS1 show promise in mouse model of Pompe disease

Feb. 25, 2020

Novel homeostatic lipid mediators show neuroprotection in rat model of cerebral ischemia

Feb. 25, 2020

Phase II results for olaparib with or without cediranib in mCRPC

Feb. 25, 2020

FDA approves Fluad Quadrivalent influenza vaccine for use in adults age 65 years and older

Feb. 25, 2020

Sojournix begins phase II study of SJX-653 for vasomotor symptoms due to menopause

Feb. 25, 2020

Glutaminase 1 is NASH target

Feb. 25, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...